On February 24, 2025, the FDA approved Medtronic's BrainSense Adaptive deep brain stimulator, a new device aimed at benefiting Parkinson's disease patients. This device, implanted in the chest and connected to the brain, adapts to manage abnormal signals contributing to involuntary muscle movements. It represents the first personalized deep brain stimulation approach, addressing the limitations of past treatments, which employed continuous, one-size-fits-all stimulation. This innovation could help rectify imbalances experienced by patients utilizing both medication and stimulation for their symptoms, promising a more effective management of the motor condition.
The FDA's approval of the Medtronic BrainSense Adaptive deep brain stimulator marks a significant advancement, offering personalized, responsive treatment for Parkinson's disease.
Continuous stimulation from previous deep brain stimulators can lead to an imbalance in treatment, causing patients to experience periods of overtreatment and undertreatment.
Collection
[
|
...
]